New York, April 28, 2016 -- Moody's Investors Service placed the ratings of St. Jude Medical, Inc.(Baa2/Prime-2) under review for downgrade. This follows news that the company has entered into a definitive agreement to be acquired by Abbott Laboratories (A2/Prime-1 ratings under review for downgrade). The transaction price is approximately $31.0 billion, including about $5.7 billion of St. Jude Medical's net debt.
Vollständigen Artikel bei Moodys lesen